Description

Product Features

Product Name	:	Elbonix
Generic Name	:	Eltrombopag
Formulation	:	Tablet
Available Pack Size	:	28’s Pot
Available Strength	:	25 mg
Registrations	:	Export Only

 

Introduction of Elbonix

Elbonix (Eltrombopag) oral tablet is available as a brand-name drug. It’s not available as a generic drug. Elbonix comes in two forms: oral tablet and oral suspension. Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Elbonix is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work.

 

Working Principle

Elbonix is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. Platelets help to reduce or prevent bleeding.

Uses Elbonix 25 mg

Eltrombopag is used for low platelet count due to ITP or HCV infection. That treat low platelet count due to chronic immune (idiopathic), thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. Eltrombopag is also use to treat severe aplastic anemia.

 

Elbonix side effects

Eltrombopag can cause mild or serious side effects. The following list contains some of the key side effects that may occur while taking eltrombopag. This list does not include all possible side effects.

For more information on the possible side effects of eltrombopag, or tips on how to deal with a troubling side effect, talk with your doctor or pharmacist.

 

More common side effects

The more common side effects of eltrombopag can include:

• Anemia
• Nausea
• Fever
• Tiredness
• Cough
• Headache
• Diarrhea
• Flu
• Loss of appetite

If these effects are mild, they may go away within a few days or a couple of weeks. If they’re more severe or don’t go away, talk to your doctor or pharmacist.

 

Interactions that increase your risk of side effects

Increased side effects from other drugs: Taking eltrombopag with certain medications raises your risk of side effects from these drugs. Examples of these drugs include:

• Bosentan, ezetimibe, glyburide, olmesartan, repaglinide, rifampin, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, sulfasalazine, and topotecan. Your doctor may lower your dosage of these drugs if needed.
• Cholesterol-lowering drugs such as rosuvastatin, atorvastatin, fluvastatin, pitavastatin, pravastatin, and simvastatin. Increased side effects can include muscle pain. Your doctor may lower the dosage of your cholesterol drugs.

 

Interactions of medicine effective

When use with eltrombopag, these drugs can make eltrombopag less effective. This means it won’t work as well to treat your condition. This is because the amount of eltrombopag in your body may be decreased. Examples of these drugs include:

• Antacids, vitamins, or supplements that contain calcium, aluminum, iron, selenium, zinc, or magnesium. To avoid interactions, you should take eltrombopag two hours before or four hours after taking any of these products.

 

Warnings for other groups

Pregnant women

There haven’t enough studies done in humans to be certain how this drug might affect a pregnancy. Research in animals has shown negative effects to the pregnancy when the mother takes the drug. However, animal studies don’t always predict the way humans would respond.

Talk to your doctor if you’re pregnant or planning to become pregnant. This drug should only use if the potential benefit justifies the potential risk.

If you become pregnant while taking this drug, call your doctor right away.

Breastfeeding women

This medication is not recommended for use while breastfeeding. This drug may pass into breast milk and cause side effects in a child who is breastfed. Talk to your doctor if you breastfeed your child. You may need to decide whether to stop breastfeeding or stop taking this medication.

 

Children

This drug has not studied in children younger than 1 year with chronic immune thrombocytopenia. It should not use in children younger than 1 year for this condition.

This drug has not studied in children younger than 2 years with definitive immunosuppressive therapy-naïve severe aplastic anemia (in combination with other medications). It should not use in children younger than 2 years for this condition. (Therapy naïve means the condition has not treated before.)

This drug has not established as safe or effective for use in children with thrombocytopenia associated with chronic hepatitis C virus infection and refractory severe aplastic anemia. It should not use in people younger than 18 years with these conditions.

 

If you miss a dose

If you miss a dose, wait and take your next scheduled dose. Do not take more than one dose of this drug in one day.

 

Visit our hepatitis C related other product here.